Navigation Links
Principles of CAR T Cell Therapy and the Pathway to Regulatory Approval, Upcoming Webinar Hosted by Xtalks
Date:5/31/2019

For many years, the primary forms of cancer treatment have been chemotherapy, radiation and surgery, but the toughest forms of cancer demand breakthrough therapies. Advances in immuno-oncology have led to the advent of Chimeric Antigen Receptor T (CAR T) cell therapy, which combines a patient’s own T cells with engineered T cell receptors known as “CARs”. The CAR enables the final product to produce chemicals in the hopes that the “enhanced” product or cells will bind to the cancer cells and kill them.

The industry has seen successes in using CAR T therapy in several blood cancers, including acute myeloid leukemia, acute lymphoblastic leukemia and lymphoma. Some of these unique therapies have already been cleared by the US Food and Drug Administration (FDA), but the pathway to the clinic comes with several challenges.

Join Brian D. Marks, BSc, DC, Senior Director, Project Delivery, Oncology at Premier Research and Ashley Jones, MSc, Project Lead, Project Management, Oncology at Premier Research in a live webinar on Tuesday, June 18, 2019 at 11am EDT (4pm BST/UK) to learn about:

  •     Principles of CAR-T cell therapy
  •     FDA-approved CAR-T cell therapies
  •     Operational and clinical pathways that bring CAR-T cell therapies to patients
  •     Challenges with clinical application

For more information or to register for the complimentary session, visit Principles of CAR T Cell Therapy and the Pathway to Regulatory Approval.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:
Candice Tang
Tel: +1 (416) 977-6555 ext 400
Email: ctang@xtalks.com

Read the full story at https://www.prweb.com/releases/principles_of_car_t_cell_therapy_and_the_pathway_to_regulatory_approval_upcoming_webinar_hosted_by_xtalks/prweb16340590.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Investors Applaud Amgen and Novartis for Support of Investor Principles on Biosimilars, Alternatives to Higher Cost Drugs
2. Chemical Publishing Company to Release New Title Boiler Water Treatment Principles and Practice: Charts and Notes for Field Use
3. VetStem Biopharma Shares the Story of Atlas Who Was Successfully Treated with VetStem Cell Therapy by Dr. Colter Negranti
4. VetStem Biopharma Shares the Success Story of Frank who was Treated with VetStem Cell Therapy by Pain Management Specialist Dr. Jamie Gaynor
5. VetStem Biopharma Shares the Story of Sonny Bar Lisa Who Was Successfully Treated With VetStem Cell Therapy
6. ASGCT Members Elect Five New Directors from CHOP, UMass, Advanced Therapy Partners, bluebird bio, and Vanderbilt University
7. VetStem Regenerative Cell Therapy Helps Arthritic Sun Bear at the World-Famous San Diego Zoo
8. VetStem Biopharma is Pleased to Share the Success Story of Bogey Who Was Treated with VetStem Cell Therapy by Dr. Ava DeCozio
9. Sheba Medical Center to Collaborate with Lonza Pharma on State-of-the-Art "Cocoon" Platform to Aid Cancer Patients' Access to Life-Saving CAR-T Immunotherapy Treatments
10. VetStem Biopharma Shares the Story of San Fransisko Who Advanced in His Dressage Career After Being Treated with VetStem Cell Therapy
11. AskBio Announces First Patient Dosed with Gene Therapy in Phase 1/2 Study of ACTUS-101 in Patients with Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2019)... ... August 15, 2019 , ... PathSensors announced today ... a member of the Institute of Food Technologists (IFT) Board of Directors, Illinois ... Joint Institute for Food Safety and Applied Nutrition (JIFSAN) Advisory Council and the ...
(Date:8/8/2019)... (PRWEB) , ... August 08, 2019 , ... ... Virtual Agents for sales and service organizations, today announced that the company’s ... Leadership Award for the IVA market . Inference will officially accept the award ...
(Date:8/6/2019)... FARMINGTON, Conn. (PRWEB) , ... August 06, 2019 ... ... that develops tools for characterizing microbiome populations down to the strain level, has ... Biome’s microbiome kits and other products to companies and research organizations in Australia, ...
(Date:8/4/2019)... MINNEAPOLIS (PRWEB) , ... August 02, 2019 , ... Cirtec ... minimally invasive devices, today announced that it has begun construction on a 30,000 sq. ... about 15 miles from San Jose. , The facility, which is expected to ...
Breaking Biology Technology:
(Date:8/27/2019)... JUPITER, Fla. (PRWEB) , ... August 27, 2019 ... ... developments in life science and drug development. This episode is scheduled to broadcast ... will explore Debiopharm, a biopharmaceutical research, development, investment and manufacturing company. The show ...
(Date:8/23/2019)... (PRWEB) , ... August 22, 2019 , ... ... rebranding to Planet121 following their acquisition in June of 2018. Along with the ... and communications. , “Our goal was to create a cohesive brand that ...
(Date:8/21/2019)... ... August 20, 2019 , ... ... the second time since BioInformatics first fielded the survey in 2016. The ... Customer Experience , from BioInformatics, part of Science and Medicine Group. More than ...
Breaking Biology News(10 mins):